Group A streptococcal vaccines

Pediatric Annals

Volumn 27, Issue 5, 1998, Pages 301-308

  Dale, James B ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT VACCINE; STREPTOCOCCUS VACCINE;

BACTERIAL INFECTION; DRUG DELIVERY SYSTEM; IMMUNE RESPONSE; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PHARYNGITIS; RABBIT; REVIEW; RHEUMATIC FEVER; SEROTYPE; STREPTOCOCCUS GROUP A; VACCINATION; VACCINE PRODUCTION;

EID: 0031800154     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-19980501-10     Document Type: Review

References (28)

1. Hasty, DL, Ofek I, Courtney HS, Doyle RJ. Multiple adhesions of streptococci. Infect Immun. 1992;60:2147-2152.
2. Lancefield RC. Current knowledge of the type specific M antigens of group A streptococci. J Immunol. 1962;89:307-313.
3. Whitnack E, Beachey EH. Antiopsonic activity of fibronogen bound to M protein on the surface of group A streptococci. J Clin Invest. 1982;69:1042-1048.
4. Fischetti VA, Horstman RD, Pancholi V. Location of the complement factor H binding site on streptococcal M protein. Infect Immun. 1995;63:149-156.
5. Dale JB, Washburn RG, Marques MB, Wessels MR. Hyaluronate capsule and surface M protein in resistance to phagocytosis of group A streptococci. Infect Immun. 1996;64:1495-1501.
6. Ji Y, Carlson B, Kondagunta A, Cleary PP. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A streptococcus. Infect Immun. 1997;65:2080-2087.
7. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev. 1995;8:411-426.
8. Lukomski S, Sreevatsan S, Amberg C, Reichardt W, Woischnik M, Podbielski A, Musser JM. Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains. J Clin Invest. 1997;99:2574-2580.
9. Kapur V, Maffei JT, Greer RS, Li LL, Adams GJ, Musser JM. Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci. Microb Pathogen. 1994;16:443-450.
10. Salvadori LG, Blake MS, McCarty M, Tai JY, Zabriskie JB. Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. J Infect Dis. 1995;171:593-600.
11. Bessen D, Fischetti VA. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun. 1988;56:2666-2672.
12. Courtney HS, Dale JB, Hasty DL. Differential effects of the streptococcal fibronectin-binding protein, FBP54, on adhesion of group A streptococci to human buccal cells and Hep-2 tissue culture cells. Infect Immun. 1996;64:2415-2419.
13. Bronze MS, Courtney HS, Dale JB. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. J Immunol. 1992;148:888-893.
14. Lancefield RC. Persistence of type-specific antibodies in man following infection with group A streptococci. J Exp Med. 1959;110:271-282.
15. Beachey EH, Stollerman GH, Johnson RH, Ofek I, Bisno AL. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. J Exp Med. 1979;150:862-877.
16. Dale JB, Beachey EH. Protective antigenic determinant of streptococcal M protein shared with sarcolemmal membrane protein of human heart J Exp Med. 1982;156:1165-1176.
17. Dale JB, Beachey EH. Multiple heart-cross-reactive epitopes of streptococcal M proteins. J Exp Med. 1985;161:113-122.
18. Fischetti VA. Streptococcal M protein: Molecular design and biological behavior. Clin Microbiol. Rev. 1989;2:285-314.
19. Beachey EH, Bronze MS, Dale JB, Kraus W, Poirier TP, Sargent SJ. Protective and autoimmune epitopes of streptococcal M protein vaccine. Vaccine. 1988;6:192-196.
20. Baird RW, Bronze MS, Kraus W, Hill HR, Veasey LG, Dale JB. Epitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium. J Immunol. 1991;146:3132-3137.
21. Bronze MS, Dale JB. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. J Immunol. 1993;151:2820-2828.
22. Dale JB, Chiang KY, Lederer JW. Recombinant tetravalent group A streptococcal M protein vaccine. J Immunol. 1993;151:2188-2194.
23. Dale JB, Simmons M, Chiang EC, Chiang KY. Recombinant, octavalent group A streptococcal M protein vaccine. Vaccine. 1996;14:944-948.
24. Dale JB, Chiang EC. Intranasal immunization with recombinant group a streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systematic challege infections. J Infect Dis. 1995;171:1038-1041.
25. Bisno AL. The concept of rheumatogenic and nonrheumatogenic group A streptococci. In: Reed SE, Zabriskie JB, eds. Streptococcal Diseases and the Immune Response. New York: Academic Press; 1980:789-796.
26. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptoccal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis. 1992;166:374-382.
27. Kiska DL, Thiede B, Caracciolo J, et al. Invasive group A streptococcal infections in North Carolina: Epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J Infect Dis. 1997;176:992-1000.
28. Nakashima K, Ichiyama S, Iinuma Y, et al. A clinical and bacteriologic investigation of invasive streptococcal infections in Japan on the basis of serotypes, toxin production, and genomic DNA fingerprints. Clin Infect Dis. 1997;25:260-266.